Dyadic opened higher at $0.39, compared with its previous close of $0.39. In the last trading session, the stock traded between $0.35 and $0.41. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Dyadic is now worth
$ 8.71
Resulting in a loss of
$ 91.29 (91.29%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.04 (-9.79%)
Day High
$0.41
Day Low
$0.35
Day Open
$0.39
Prev Close
$0.39
Volume
1,07,625
1W Return
-4.89%
1M Return
-16.07%
3M Return
-66.44%
6M Return
-51.67%
1Y Return
-64.19%
Market Cap ($ Mn)
14
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-549.28%
ROCE
-113.20%
EPS (TTM)
$-0.06
1 Week
-4.89%
1 Month
-16.07%
3 Months
-66.44%
6 Months
-51.67%
9 Months
-56.00%
Empery Asset Management holds 8.35% stake in Dyadic International
Empery Asset Management reported an 8.35% stake in Dyadic International. The ownership figure is based on data as of September 30. The disclosure was made via a Schedule 13G filing to the SEC. The filing indicates a passive investment position rather than active control.
28 days agoDyadic International secures $2.9 million via registered direct offering
Dyadic International (NASDAQ: DYAI) has finalized agreements for a $2.9 million registered direct offering and warrant placement. The deal includes 3.625 million shares at $0.795 each and matching warrants exercisable at $0.84. Closing is expected on August 14, 2026, with proceeds directed toward general corporate purposes and working capital.
3mo agoDyadic International Q2 Results: EPS Misses Estimate, Sales Down 0.6% YoY
Dyadic International posted Q2 EPS of $(0.06), missing the $(0.04) estimate by 50%. Sales fell 0.57% YoY to $961.138K, underperforming the $993.333K revenue estimate by 3.24%.
3mo agoDyadic Applied BioSolutions signs dairy protein development deal
Dyadic Applied BioSolutions expands its non-animal dairy portfolio with a new European partnership. The deal uses the Dapibus platform for precision fermentation, adding to existing projects with Inzymes ApS and BRIG BIO. Revenue will come from development fees and commercial participation.
3mo agoDyadic Applied BioSolutions Q2 Results: Conference call set for Aug 12
Dyadic Applied BioSolutions will announce Q2 2026 financial results on August 12, 2026. The conference call at 5:00 p.m. ET will cover performance in protein production platforms. Investors can dial in or watch via webcast, with questions accepted via email beforehand.
3mo agoDyadic C1 platform gains global validation, expands commercial reach
Dyadic International, Inc. announced progress in global health collaborations validating its C1 protein production platform, securing a full $3.1 million Gates Foundation grant. Partnerships with CEPI and Scripps Research demonstrated rapid production capabilities, supporting a $25 billion commercial opportunity in biologics manufacturing.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Dyadic is now worth
$ 8.71
Resulting in a loss of
$ 91.29 (91.29%)
Note: Past profits do not guarantee future returns.
